JP2013544288A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544288A5
JP2013544288A5 JP2013542199A JP2013542199A JP2013544288A5 JP 2013544288 A5 JP2013544288 A5 JP 2013544288A5 JP 2013542199 A JP2013542199 A JP 2013542199A JP 2013542199 A JP2013542199 A JP 2013542199A JP 2013544288 A5 JP2013544288 A5 JP 2013544288A5
Authority
JP
Japan
Prior art keywords
virus
viral
liquid
preparation
viral composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013542199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544288A (ja
JP6034797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063037 external-priority patent/WO2012075376A2/en
Publication of JP2013544288A publication Critical patent/JP2013544288A/ja
Publication of JP2013544288A5 publication Critical patent/JP2013544288A5/ja
Application granted granted Critical
Publication of JP6034797B2 publication Critical patent/JP6034797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013542199A 2010-12-02 2011-12-02 凍結乾燥されたウイルス製剤 Active JP6034797B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41902010P 2010-12-02 2010-12-02
US61/419,020 2010-12-02
PCT/US2011/063037 WO2012075376A2 (en) 2010-12-02 2011-12-02 Lyophilized viral formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016170628A Division JP6433954B2 (ja) 2010-12-02 2016-09-01 凍結乾燥されたウイルス製剤

Publications (3)

Publication Number Publication Date
JP2013544288A JP2013544288A (ja) 2013-12-12
JP2013544288A5 true JP2013544288A5 (cg-RX-API-DMAC7.html) 2015-01-22
JP6034797B2 JP6034797B2 (ja) 2016-11-30

Family

ID=46162458

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013542199A Active JP6034797B2 (ja) 2010-12-02 2011-12-02 凍結乾燥されたウイルス製剤
JP2016170628A Active JP6433954B2 (ja) 2010-12-02 2016-09-01 凍結乾燥されたウイルス製剤
JP2018153546A Withdrawn JP2018172443A (ja) 2010-12-02 2018-08-17 凍結乾燥されたウイルス製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016170628A Active JP6433954B2 (ja) 2010-12-02 2016-09-01 凍結乾燥されたウイルス製剤
JP2018153546A Withdrawn JP2018172443A (ja) 2010-12-02 2018-08-17 凍結乾燥されたウイルス製剤

Country Status (15)

Country Link
US (2) US9044498B2 (cg-RX-API-DMAC7.html)
EP (1) EP2646052B1 (cg-RX-API-DMAC7.html)
JP (3) JP6034797B2 (cg-RX-API-DMAC7.html)
KR (1) KR102023207B1 (cg-RX-API-DMAC7.html)
CN (1) CN103269716B (cg-RX-API-DMAC7.html)
AU (1) AU2011336410B2 (cg-RX-API-DMAC7.html)
CA (1) CA2819236A1 (cg-RX-API-DMAC7.html)
DK (1) DK2646052T3 (cg-RX-API-DMAC7.html)
EA (1) EA201390812A1 (cg-RX-API-DMAC7.html)
ES (1) ES2630012T3 (cg-RX-API-DMAC7.html)
IL (1) IL226646B (cg-RX-API-DMAC7.html)
MX (1) MX349294B (cg-RX-API-DMAC7.html)
SG (1) SG190419A1 (cg-RX-API-DMAC7.html)
TW (1) TW201233803A (cg-RX-API-DMAC7.html)
WO (1) WO2012075376A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548442T3 (es) 2007-03-12 2015-10-16 Oncolytics Biotech Inc. Reovirus que tienen secuencias modificadas
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
TW201307561A (zh) * 2011-04-29 2013-02-16 腫瘤防治生化科技公司 使用凝膠滲透層析法純化病毒之方法
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
CA3042689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations
CR20200212A (es) * 2017-10-16 2020-07-17 Serum Institute Of India Pvt Ltd Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las misma
CN110279693B (zh) * 2019-07-25 2021-06-15 军事科学院军事医学研究院微生物流行病研究所 一种组合物在制备预防和/或治疗发热伴血小板减少综合征病毒的药物中的应用
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
ES2097120T3 (es) 1989-07-24 1997-04-01 Bayer Ag Estabilizacion de proteinas altamente purificadas.
WO1993018790A1 (en) 1992-03-24 1993-09-30 Csatary Laszlo K Vaccine containing live virus for therapy of viral diseases and malignancies
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
AU7971194A (en) 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
PL183781B1 (pl) 1994-05-16 2002-07-31 Merck & Co Inc Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
US6165773A (en) 1995-10-25 2000-12-26 Provalis Uk Limited Methods of preserving viruses
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
JP4653262B2 (ja) 1996-09-26 2011-03-16 メルク・シャープ・エンド・ドーム・コーポレイション ロタウイルスワクチン製剤類
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
CA2274755A1 (en) 1996-12-20 1998-07-02 Su-Pi Sheu Stabilizers for lyophilized vaccines
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
JP4358434B2 (ja) 1998-02-17 2009-11-04 シェーリング コーポレイション ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
BRPI9912485B8 (pt) 1998-07-28 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services composição imunogênica multivalente
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
JP4932086B2 (ja) 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
DK1212045T3 (en) 1999-08-24 2016-11-28 Abic Biological Laboratories Ltd VACCINE COMPOSITION AND METHOD OF USING IT
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
NZ552576A (en) 2000-06-08 2008-06-30 Powderject Vaccines Inc Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
JP5063852B2 (ja) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
US20040033239A1 (en) 2001-03-06 2004-02-19 Evans Robert K Adenovirus formulations
MXPA03007535A (es) 2001-03-16 2003-12-11 Oncolytics Biotech Inc Metodo para extraer virus de cultivo celular.
WO2002101412A2 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
GB0124710D0 (en) 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
CN1287770C (zh) 2001-11-19 2006-12-06 贝克顿迪肯森公司 颗粒型的药物组合物
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
EP1465664A1 (en) 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilized formulations of adenovirus
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
ATE352316T1 (de) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US6752740B2 (en) 2002-11-12 2004-06-22 Jeffery T. Semmes Continuously variable transmission
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
NZ545639A (en) * 2003-09-02 2009-04-30 Glaxosmithkline Biolog Sa Cross-protective live attenuated human rotavirus vaccine
US20070148765A1 (en) 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
CA2549197C (en) 2003-12-17 2015-04-14 Wyeth Methods for producing storage stable viruses and immunogenic compositions thereof
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
GB0404586D0 (en) 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
JP2007526329A (ja) 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
ES2644416T3 (es) 2004-06-02 2017-11-28 Universal Stabilization Technologies, Inc. Conservación mediante vaporización
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
CA2579471A1 (en) 2004-09-28 2006-04-06 Alza Corporation Stabilization of alum-adjuvanted immunologically active agents
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2584815C (en) * 2004-11-05 2014-03-25 Wellstat Biologics Corporation Stable and filterable enveloped virus formulations
DE602005009402D1 (de) 2004-12-09 2008-10-09 Precimed Sa Operationsinstrumentenhalter für leichtere sterilisation
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
HRP20110803T1 (hr) * 2005-09-16 2011-11-30 Merial Ltd. Stabilizatori za cjepiva osušena zamrzavanjem
CN1765181A (zh) 2005-10-19 2006-05-03 路兴波 高效抗病毒制剂
AU2007240797B2 (en) 2006-04-20 2013-05-23 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP1878791A1 (en) 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
WO2008018411A1 (en) 2006-08-07 2008-02-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for production of live smallpox vaccine
WO2008039761A2 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
DK2099485T3 (en) 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
EP2086581B1 (en) * 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
ES2951660T3 (es) 2006-12-27 2023-10-24 Zoetis Services Llc Procedimientos de administración de vacunas
WO2008106646A2 (en) 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
ES2548442T3 (es) * 2007-03-12 2015-10-16 Oncolytics Biotech Inc. Reovirus que tienen secuencias modificadas
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
DK2144998T3 (en) 2007-04-06 2017-04-10 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
TW200909581A (en) 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
US8241886B2 (en) * 2007-09-25 2012-08-14 Aridis Pharmaceuticals Formulations for preservation of rotavirus
EP2394657A1 (en) 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
US8057796B2 (en) 2007-11-12 2011-11-15 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
MX2010009351A (es) * 2008-02-25 2011-03-04 Novavax Inc Particulas similares a virus cristalizadas con azucar.
EP2805731B1 (en) * 2009-09-03 2018-10-31 Ablynx N.V. Stable formulations of polypeptides and uses thereof
CA2819246C (en) * 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
TW201307561A (zh) * 2011-04-29 2013-02-16 腫瘤防治生化科技公司 使用凝膠滲透層析法純化病毒之方法
JP6065096B2 (ja) 2015-12-25 2017-01-25 ダイキン工業株式会社 調湿装置

Similar Documents

Publication Publication Date Title
JP2013544288A5 (cg-RX-API-DMAC7.html)
JP2014502275A5 (cg-RX-API-DMAC7.html)
ES2676656T3 (es) Composición estabilizante de almacenamiento en seco para materiales biológicos
CN102727903B (zh) 一种高致病性猪繁殖与呼吸综合征活疫苗jxa1-r株耐热冻干保护剂及制备方法
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
JP5307801B2 (ja) 凍結乾燥フォームによる生物活性材料の防腐
KR102755215B1 (ko) 특히 생 약독화 재조합 플라비바이러스를 포함하는 안정한 백신 조성물 및 그의 제조 방법
CN103041383B (zh) 一种活疫苗的耐热冻干保护剂、活疫苗冻干粉及其制备方法
JP4138314B2 (ja) ロタウイルスワクチン調合物
US20110177119A1 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
EP2143440A1 (fr) Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN103041399B (zh) 一种耐热保护剂及其应用
JP6034797B2 (ja) 凍結乾燥されたウイルス製剤
JP2012531442A5 (cg-RX-API-DMAC7.html)
CN102727904A (zh) 一种高致病性猪繁殖与呼吸综合征-伪狂犬病二联活疫苗耐热保护剂及制备方法
CN106794145A (zh) 热稳定冻干轮状病毒疫苗制剂及其制备方法
CN106063933A (zh) 通用疫苗冻干保护剂及其应用
JP2017510585A5 (cg-RX-API-DMAC7.html)
JP2019031543A (ja) 弱毒生アルファウイルス製剤のための組成物および方法
WO2019028976A1 (zh) 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
CN103893776B (zh) 羊传染性脓疱病毒细胞弱毒疫苗耐热冻干保护剂及其制备方法和应用
Lee et al. Cell-based therapy for acute lung injury: are we there yet?
HK1236813A1 (en) A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
EA046342B1 (ru) Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус и процесс их приготовления
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations